- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02547714
Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Aichi
-
Nagoya city, Aichi, Japan, 467-8602
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka-city, Fukuoka, Japan, 814-0180
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara-city, Kanagawa, Japan, 259-1193
- Novartis Investigative Site
-
-
Osaka
-
Osaka-city, Osaka, Japan, 550-0012
- Novartis Investigative Site
-
-
Tochigi
-
Shimotsuke-city, Tochigi, Japan, 329-0498
- Novartis Investigative Site
-
-
Tokyo
-
Chiyoda-ku, Tokyo, Japan, 102-8798
- Novartis Investigative Site
-
Itabashi-ku, Tokyo, Japan, 173-8610
- Novartis Investigative Site
-
Itabashi-ku, Tokyo, Japan, 173-8606
- Novartis Investigative Site
-
Minato-ku, Tokyo, Japan, 105-8471
- Novartis Investigative Site
-
Shinagawa-ku, Tokyo, Japan, 141 8625
- Novartis Investigative Site
-
Shinjuku-Ku, Tokyo, Japan, 169-0073
- Novartis Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Plaque psoriasis diagnosed for at least 6 months before baseline - Treated with cyclosporine A for at least 12 weeks prior to baseline
Currently treated with cyclosporine A at baseline for psoriasis but is a primary or secondary inadequate response as defined at baseline by:
- PASI score of 10 or greater and
- IGA mod 2011 score of 2 or greater (based on a scale of 0 to 4)
Exclusion Criteria:
- Forms of psoriasis other than plaque (e.g., pustular, erythrodermic and guttate psoriasis). -Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel blockers or lithium).
- Patients who have to discontinue cyclosporine A treatment due to side effects like renal impairment (serum creatinine exceeding 176.8 μmol/L [2.0 mg/dL]) and hypertension at screening.
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Secukinumab (AIN457) 300 mg
Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
|
Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75)
Tidsram: Week 16
|
PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).
The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI.
For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum).
Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4).
PASI 75 was defined as participants achieving >= 75% improvement from baseline.
|
Week 16
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Mean Percent Change From Baseline in PASI Score
Tidsram: Week 4
|
PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).
The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI.
For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum).
Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4).
A negative change from baseline indicates improvement.
|
Week 4
|
Percentage of Participants Achieving PASI 50 or PASI 75
Tidsram: Week 4
|
PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 50 and PASI 75 were defined as participants achieving >= 50% or >= 75% improvement from baseline, respectively. |
Week 4
|
Percentage of Participants Achieving PASI 90 and Investigator's Global Assessment (IGA) of 0 or 1 Response
Tidsram: Week 16
|
PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area * area score weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4). PASI 90 was defined as participants achieving >= 90% improvement from baseline. The IGA scale is static, i.e. it referred exclusively to the participant's disease at the time of assessment and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. |
Week 16
|
Mean Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score
Tidsram: Week 16
|
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts.
It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities.
Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much).
"Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses.
Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
A negative mean percentage change from baseline indicates improvement.
|
Week 16
|
Percentage of Participants Achieving DLQI 0 or 1
Tidsram: Week 16
|
The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts.
It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities.
Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much).
"Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses.
Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.
|
Week 16
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CAIN457AJP01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Plack Psoriasis
-
ProgenaBiomeRekryteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hårbotten | Psoriasisplack | Psoriasis Universalis | Psoriasis ansikte | Psoriasis Nagel | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaFörenta staterna
-
Clin4allRekryteringPsoriasis i hårbotten | Psoriasis Nagel | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrankrike
-
AmgenAvslutadPsoriasis-Psoriasis | Psoriasis av placktypFörenta staterna
-
Centre of Evidence of the French Society of DermatologyRekryteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hårbotten | Psoriasisplack | Psoriasis Universalis | Psoriasis Palmaris | Psoriatisk erytrodermi | Psoriasisnagel | Psoriasis Guttate | Psoriasis invers | Psoriasis PustulösFrankrike
-
UCB Biopharma S.P.R.L.AvslutadMåttlig till svår psoriasis | Generaliserad pustulös psoriasis och erytrodermisk psoriasisJapan
-
TakedaRekryteringGeneraliserad pustulös psoriasis | Erytrodermisk psoriasisJapan
-
Janssen Pharmaceutical K.K.RekryteringGeneraliserad pustulös psoriasis | Erytrodermisk psoriasisJapan
-
Eli Lilly and CompanyAvslutadGeneraliserad pustulös psoriasis | Erytrodermisk psoriasisJapan
-
Innovaderm Research Inc.AvslutadPsoriasis i hårbotten | Pustulös Palmo-plantar Psoriasis | Icke-pustulös Palmo-plantar Psoriasis | Armbågspsoriasis | Psoriasis i underbenetKanada
-
PfizerAvslutadPsoriasis Vulgaris | Pustulös psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
Kliniska prövningar på Secukinumab (AIN457)
-
Novartis PharmaceuticalsAvslutadLupus nefritKina, Kroatien, Tjeckien, Ryska Federationen, Kalkon, Australien, Spanien, Thailand, Argentina, Förenta staterna, Danmark, Grekland, Rumänien, Tyskland, Korea, Republiken av, Indien, Brasilien, Japan, Peru, Portugal, Italien, Taiwan, Vietna... och mer
-
Novartis PharmaceuticalsAvslutadPsoriasisStorbritannien, Irland
-
Novartis PharmaceuticalsRekryteringJättecellarterit | Polymyalgia RheumaticaFörenta staterna, Spanien, Schweiz
-
Academisch Medisch Centrum - Universiteit van Amsterdam...NovartisAvslutadSpondylarthropatierNederländerna
-
Novartis PharmaceuticalsAvslutadAnkyloserande spondylitIndien, Kalkon, Belgien, Thailand, Förenta staterna, Tjeckien, Grekland, Ryska Federationen, Bulgarien, Guatemala, Italien, Korea, Republiken av, Malaysia, Sverige, Colombia, Filippinerna, Polen, Brasilien
-
Novartis PharmaceuticalsAvslutadSköldkörtelögonsjukdom | Graves orbitopatiTyskland
-
Novartis PharmaceuticalsAvslutadAstmaTyskland, Storbritannien
-
Novartis PharmaceuticalsAktiv, inte rekryterandeIcke-radiografisk axiell spondyloartritKina
-
Novartis PharmaceuticalsAvslutadPlack PsoriasisTyskland, Storbritannien, Belgien, Tjeckien, Estland, Italien, Frankrike, Israel, Spanien, Bulgarien, Litauen, Portugal, Polen, Rumänien, Lettland, Grekland, Slovakien
-
Novartis PharmaceuticalsAvslutadPlack PsoriasisFörenta staterna